· Net revenue increased by 15 percentage points and amounted to SEK 21.1 million (18.3).
· The net loss after tax totaled SEK 16.5 million (17.9). This represented an improvement in result of SEK 1.4 million compared to the corresponding period the previous year.
· Earnings per stock unit amounted to SEK -0.03 (-0.15).
· The aim of achieving a positive cash flow before changes in working capital on a monthly basis was moved forward to the second half of 2013 due to low sales growth in the USA. The sales development is still weak and the impact of the litigations it is uncertain and therefore the Board can at present not determine when the cash flow will be positive.
· The Board proposes that no dividend be paid for 2012.
· The license agreement with Biomet Sportsmedicine was terminated in April.
· The USA study of Artelon® Tissue Reinforcement for rotator cuff injuries has been published. The study shows positive results with regard to functioning of the shoulder and patients' perceived improved quality of life.

Fourth quarter

· Net revenue amounted to SEK 5.5 million (4.0) an improvement with 1.5 MSEK. European sales increased by 247 percentage points and the US sales by 25 percentage points compared to previous period.
· The net loss after tax totaled SEK 6.4 million (6), a decreased by 0.4 MSEK compared to previous period due to higher legal costs in terms of increased legal costs caused by the ongoing insurance dispute.   

· Earnings per stock unit amounted to SEK -0.01 (-0.05).
· Preliminary positive results presented from a two-year study of Artelon® CMC Spacer.

Events after the year-end

· Artimplant prolongs its funding agreement regarding costs for trials in USA and recovers previous legal costs of SEK 5 million.
· Artimplant has requested arbitration in the insurance dispute.
· The Company is in need of a capital injection, the Board has therefore decided to review its strategic options

distributed by